{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:10:20Z","timestamp":1783350620349,"version":"3.54.6"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.breast.2021.04.011","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T08:54:51Z","timestamp":1620809691000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-5399","authenticated-orcid":false,"given":"Filomena","family":"Ficarazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2750-9160","authenticated-orcid":false,"given":"Manuela","family":"Vecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7431-8332","authenticated-orcid":false,"given":"Marco A.","family":"Pierotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2021.04.011_bib1","doi-asserted-by":"crossref","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.breast.2021.04.011_bib2","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","author":"Kuchenbaecker","year":"2013","journal-title":"J\u00a0Am Med Assoc"},{"issue":"3","key":"10.1016\/j.breast.2021.04.011_bib3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1006\/gyno.1998.5081","article-title":"Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient","volume":"70","author":"Randall","year":"1998","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.breast.2021.04.011_bib4","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2021.04.011_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.944","article-title":"Classification of the spliceogenic BRCA1c.4096+3A>G variant as likely benign based on cosegregation data and identification of a healthy homozygous carrier","author":"Byrjalsen","year":"2017","journal-title":"Clin Case Rep"},{"issue":"5","key":"10.1016\/j.breast.2021.04.011_bib6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/humu.23406","article-title":"Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations","volume":"39","author":"Rebbeck","year":"2018","journal-title":"Hum Mutat"},{"issue":"3","key":"10.1016\/j.breast.2021.04.011_bib7","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3390\/cancers13030532","article-title":"Analysis of Italian BRCA1\/2 pathogenic variants identifies a private spectrum in the population from the bergamo province in northern Italy","volume":"13","author":"Figlioli","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.breast.2021.04.011_bib8","doi-asserted-by":"crossref","first-page":"e86924","DOI":"10.1371\/journal.pone.0086924","article-title":"Characterization of an Italian founder mutation in the RING-finger domain of BRCA1","volume":"9","author":"Caleca","year":"2014","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.breast.2021.04.011_bib9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s11523-019-00680-2","article-title":"PARP inhibition in cancer: an update on clinical development","volume":"14","author":"Sachdev","year":"2019","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.breast.2021.04.011_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","author":"De Bono","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2021.04.011_bib12","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-genom-083118-015253","article-title":"Population screening for inherited predisposition to breast and ovarian cancer","author":"Manchanda","year":"2020","journal-title":"Annu Rev Genom Hum Genet"},{"key":"10.1016\/j.breast.2021.04.011_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071929","article-title":"Economic evaluation of population-based BRCA1\/BRCA2 mutation testing across multiple countries and health systems","author":"Manchanda","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2021.04.011_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/1471-0528.15657","article-title":"A\u00a0commentary on population genetic testing for primary prevention: changing landscape and the need to change paradigm","author":"Manchanda","year":"2019","journal-title":"BJOG"},{"issue":"5","key":"10.1016\/j.breast.2021.04.011_bib15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A\u00a0population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2021.04.011_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju379","article-title":"Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial","author":"Manchanda","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2021.04.011_bib17","article-title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","volume":"2014","author":"Gabai-Kapara","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.breast.2021.04.011_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.25.0712","article-title":"Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women","author":"Metcalfe","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.breast.2021.04.011_bib19","first-page":"2162","article-title":"Population genomic screening of all young adults in ahealth-care system: a cost-effectiveness analysis","volume":"21","author":"Zhang","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.breast.2021.04.011_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-019-02262-0","article-title":"SEOM clinical guidelines in hereditary breast and ovarian cancer","author":"Gonzalez-Santiago","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.breast.2021.04.011_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajhg.2021.02.005","article-title":"Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance","author":"Richardson","year":"2021","journal-title":"AJHG"},{"key":"10.1016\/j.breast.2021.04.011_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.4428","article-title":"Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer","author":"Kemp","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.breast.2021.04.011_bib23","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-012-2257-y","article-title":"Hereditary breast and Ovarian cancer and other hereditary syndromes: using technology to identify carriers","author":"Drohan","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2021.04.011_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4029-y","article-title":"German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Prevalence of pathogenic BRCA1\/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history","author":"Engel","year":"2018","journal-title":"BMC Canc"},{"key":"10.1016\/j.breast.2021.04.011_bib25","article-title":"Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer","author":"Guideline","year":"2013","journal-title":"Cardiff, UK: Nat Collaborat Centr Canc"},{"key":"10.1016\/j.breast.2021.04.011_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/ejhg.2014.161","article-title":"Evaluation of the Dutch BRCA 1\/2 clinical genetic center referral criteria in an unselected early breast cancer population","author":"Van den Broek","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.breast.2021.04.011_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5829-4","article-title":"BRCA germline mutation test for all woman with ovarian cancer?","author":"Paradiso","year":"2019","journal-title":"BMC Canc"},{"key":"10.1016\/j.breast.2021.04.011_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10010007","article-title":"Healthcare utilization and costs after receiving a positive BRCA1\/2 result from a genomic screening program","author":"Hao","year":"2020","journal-title":"J\u00a0Personalized Med"},{"issue":"1","key":"10.1016\/j.breast.2021.04.011_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","article-title":"Polygenic risk scores for prediction of breast cancer and breast cancer subtypes","volume":"104","author":"Mavaddat","year":"2019","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.breast.2021.04.011_bib30","doi-asserted-by":"crossref","first-page":"djw302","DOI":"10.1093\/jnci\/djw302","article-title":"Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers","volume":"109","author":"Kuchenbaecker","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.breast.2021.04.011_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13058-020-01260-3","article-title":"Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field","volume":"22","author":"Yanes","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2021.04.011_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajhg.2021.02.005","article-title":"Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance","author":"Richardson","year":"2021","journal-title":"AJHG"},{"key":"10.1016\/j.breast.2021.04.011_bib33","article-title":"Il nuovo modello mutazionale in Oncologia. Cosa cambia nella pratica clinica e assistenziale, nella ricerca e nelle procedure regolatorie","author":"Martini","year":"2019","journal-title":"Il Pensiero Sci Ed"},{"key":"10.1016\/j.breast.2021.04.011_bib34","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.2147\/OTT.S99807","article-title":"Next-generation sequencing: advances and applications in cancer diagnosis","volume":"9","author":"Serrat\u00ec","year":"2016","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.breast.2021.04.011_bib35","article-title":"Rapid response report: summary with critical appraisal","year":"2014","journal-title":"Next Gener Seq: Rev Cost Effectiv Guidelines"},{"issue":"1","key":"10.1016\/j.breast.2021.04.011_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ht9010001","article-title":"Applications of Next generation sequencing to the analysis of familial breast\/ovarian cancer","volume":"9","author":"Zelli","year":"2020","journal-title":"High Throughput"},{"issue":"Suppl","key":"10.1016\/j.breast.2021.04.011_bib37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/annonc\/mdq661","article-title":"Unclassified variants in BRCA genes: guidelines for interpretation","volume":"1","author":"Radice","year":"2011","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.breast.2021.04.011_bib39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00439-019-01970-5","article-title":"Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives","volume":"138","author":"XuJ","year":"2019","journal-title":"Hum Genet"},{"issue":"4","key":"10.1016\/j.breast.2021.04.011_bib40","first-page":"230","article-title":"Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol","volume":"2","author":"Jiang","year":"2017"},{"key":"10.1016\/j.breast.2021.04.011_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2019.12.007","article-title":"Artificial intelligence in cancer diagnosis and prognosis: opportunities and challenges","volume":"471","author":"Huang","year":"2020","journal-title":"Canc Lett"},{"key":"10.1016\/j.breast.2021.04.011_bib42","first-page":"604","article-title":"Evicase: an evidence-based case structuring approach for personalized healthcare","volume":"180","author":"Carmeli","year":"2012","journal-title":"Stud Health Technol Inf"},{"key":"10.1016\/j.breast.2021.04.011_bib43","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.3323","article-title":"A\u00a0cost-effectiveness analysis of multigene testing for all patients with breast cancer","author":"Sun","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2021.04.011_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000328","article-title":"BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer","author":"Norum","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2021.04.011_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpobgyn.2020.02.007","article-title":"Population-based genetic testing for Women's cancer prevention","author":"Evans","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.breast.2021.04.011_bib47","doi-asserted-by":"crossref","DOI":"10.3747\/co.24.3828","article-title":"Coming of age in Canada: a study of population-based genetic testing for breast and ovarian cancer","author":"Akbari","year":"2017","journal-title":"Curr Oncol"},{"key":"10.1016\/j.breast.2021.04.011_bib48","author":"Di Brino","year":"2020","journal-title":"Glob Reg Health Technol Assess"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977621003714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977621003714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:44:07Z","timestamp":1760777047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977621003714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":45,"alternative-id":["S0960977621003714"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2021.04.011","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2021.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}